• Radiopharm Theranostics moved its Phase 1 HEAT trial of 177Lu-RAD202 into Cohort 4 following a positive DSMC recommendation.
• The trial will test a higher dose level in patients with HER2-positive advanced solid tumors, extending evaluation of the radiotherapeutic candidate.
• No new results were presented; the update reflects a safety review that supported continued dose escalation.
• Earlier diagnostic work in HER2-positive breast cancer patients showed proof-of-concept with favorable safety and tumor targeting, supporting further development.
• The HEAT study is running at clinical centers in Australia; the prior dose-level update was released on April 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608200700PRIMZONEFULLFEED1001258433) on August 20, 2026, and is solely responsible for the information contained therein.